Trial reportRespiratory research2020
Effect of average volume-assured pressure support treatment on health-related quality of life in COPD patients with chronic hypercapnic respiratory failure: a randomized trial.
Trial report in Respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06047405 (NIV for Hypercapnic Respiratory Failure), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- The autopilot dilemma: can algorithms truly replace the clinician's touch in home ventilation?Sleep · 2026Article
- Non-Invasive Respiratory Support for Acute Cardiogenic Pulmonary Edema in the Acute Care Setting.Current heart failure reports · 2025Review
- Clinical review of non-invasive ventilation.The European respiratory journal · 2024Review
- Hypercapnia as an absolute exclusion criteria for bronchoscopic lung volume reduction.Respiratory medicine case reports · 2024Article
- Randomized Controlled Trials on Chronic Obstructive Pulmonary Disease in Africa: A Systematic Review.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2023Article
- [Hypercapnic respiratory failure with insufficient response to fixed-level PS-NIV: Is AVAPS the end solution?]Tuberkuloz ve toraks · 2023Article
- Ventilators, Settings, Autotitration Algorithms.Journal of clinical medicine · 2023Review
- Intelligent Volume-Assured Pressure Support vs. Spontaneous/Timed Mode as a Weaning Strategy in COPD-Evaluation of a New Ventilation Strategy.Advances in respiratory medicine · 2022Article
- PAP therapy and readmission rates after in-hospital laboratory titration polysomnography in patients with hypoventilation.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022Article
- Use of average volume-assured pressure support as a therapeutic option in patients with central sleep apnea syndrome.Sleep & breathing = Schlaf & Atmung · 2022Article
- APAP, BPAP, CPAP, and New Modes of Positive Airway Pressure Therapy.Advances in experimental medicine and biology · 2022Review
- Pediatric Average Volume Assured Pressure Support.Frontiers in pediatrics · 2022Review
- Non-invasive positive pressure ventilation with average volume assured pressure support may benefit patients with acute hypercapnic respiratory failure.Clinical and experimental emergency medicine · 2020Article
- Novel modes of non-invasive ventilation in chronic respiratory failure: a narrative review.Journal of thoracic disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term effect of average volume-assured pressure support (AVAPS) on health-related quality of life (HRQOL) in chronic obstructive pulmonary disease (COPD) patients with chronic hypercapnic respiratory failure (CHRF) remains unclear. The objective of this study is to identify the long-term effect of AVAPS in COPD patients with CHRF through assessment of HRQOL, exercise tolerance after six months duration.
methodsIn this randomized, controlled, parallel-group study, 40 stable hypercapnic COPD patients were randomized in a 1:1 ratio to receive either spontaneous timed AVAPS (ST/AVAPS) (intervention) or Bilevel positive airway pressure (ST/BiPAP) (control). HRQL was measured with the Short Form 12 Health Survey Questionnaire (SF-12). Exercise tolerance assessed by 6 min walking distance. Analyses were done between groups from baseline to the average of six months measurements.
resultsAVAPS led to significant 6 months improvements in several domains of (SF-12) compared to the control group, with the greatest improvement seen in general health [treatment effect of 8.2 points (95% confidence interval [95% CI 3.2 to 11.7; p = 0.001)], vitality (treatment effect 5.4 points [95% CI 1.4 to 9.3]; p = 0.001), physical functioning 5.5 points [95% CI 1.1 to 9.8]; p = 0.001) and bodily pain 5.1 points [95% CI 3.4 to 8.8]; p = 0.002). The physical health summary score improved by 3.7 points (95% CI 1.2 to 5.8; p = 0.001), but no significant improvement in the emotional or social role functioning, mental health subscale was noted. AVAPS also resulted in improvement 6 min walking distance 9.2 points (95% CI - 1 to - 15];p = 0.001). A significant reduction in the daytime (PaCO2) was observed after 6 months in those treated with AVAPS.
conclusionsIn COPD patients with hypercapnic respiratory failure, AVAPS improved exercise tolerance and multiple domains of HRQOL over six months of follow-up, with the significant improvement observed in general health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.